The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
BB, I don't know if you are correct about going above 7% or not but it doesn't explain all the other thresholds that we didn't get a TR-1. 11%, 10%, 9%, 8% and 6% (there was one for 7%) although this was down to dilution and not selling.
I wouldn't see DSM selling out as a negative either. It would just be nice to know if they do :)
They sold just shy of 13 million (12,845,872) sometime after July 23 and IMO it has been pretty recent.
12,845,872 @ around 0.6p = £77,075
Question is. What would DSM(V) be using this cash for?
Promotion of FF and Gut health B to B perhaps???
The cost of ending the AA and entering the new agreement???
...........
Shouldn't post so early in the morning.
Looks like its the dates on the website (on the right) that are wrong.
https://www.longevitymedsummit.com/clinique-la-prairie/
DP64,
Its not a new product and has been on the go since April 2021. I was just pointing out that they had a couple of keynote speakers at the (what I thought was an) upcoming summit.
Unfortunately I am a year to late with my post. lol.
Doh!
The worlds most expensive Fruitflow product.
Longevity med summit.
May 8-9 2024
"Science Shows Clinique La Prairie´s Anti-Ageing CLP Holistic Complex Works"
https://www.longevitymedsummit.com/clinique-la-prairie/
https://www.longevitymedsummit.com/simone-gibertoni/
https://cliniquelaprairie-hh.com/product/age-defy-regeneressence-and-immunity-supplements-2-x-120-capsules/
"Among the existing products, protein powder and Jianliduo have obtained new approvals"
The above 2 By-Health products are amongst their biggest revenue earners and already have Blue Cap so what could the new approvals include?
Is it 2 early to join the dots?????
"By-Health: Investor Relations Activity Record Form on April 11, 2024"
"Q: What new products can the company launch this year?"
A: "In August last year, in terms of new function development, the company took the lead in the industry to submit a new function application and product registration application that "helps maintain normal platelet aggregation function", and is currently actively promoting it. Among the existing products, protein powder and Jianliduo have obtained new approvals, and we strive to launch new products within the year."
Still pretty vague but I believe this is the first time By-Health have given any indication on timelines for a FF product.
https://data.eastmoney.com/notices/detail/300146/AN202404111630161330.html
BB,
You could be right and that's another possibility.
I would have thought that an RNS might have been required for such a "substantial transaction" but that could be classed as "in the ordinary course of business" so maybe not.
As alfista pointed out, until we get an update or the Y/E results its all pretty much guesswork.